WO2007124668A1 - Composition pharmaceutique comportant un concentré élevé de polydatine - Google Patents

Composition pharmaceutique comportant un concentré élevé de polydatine Download PDF

Info

Publication number
WO2007124668A1
WO2007124668A1 PCT/CN2007/001233 CN2007001233W WO2007124668A1 WO 2007124668 A1 WO2007124668 A1 WO 2007124668A1 CN 2007001233 W CN2007001233 W CN 2007001233W WO 2007124668 A1 WO2007124668 A1 WO 2007124668A1
Authority
WO
WIPO (PCT)
Prior art keywords
polydatin
cyclodextrin
aqueous solution
pharmaceutical composition
composition according
Prior art date
Application number
PCT/CN2007/001233
Other languages
English (en)
Chinese (zh)
Inventor
Guanghui Yao
Jinhua Zhao
Hui Kang
Wei Qu
Yong Li
Lijuan Zhang
Jing Li
Lin Yu
Kesen Zhao
Original Assignee
Shenzhen Neptunus Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Neptunus Pharmaceutical Co., Ltd. filed Critical Shenzhen Neptunus Pharmaceutical Co., Ltd.
Priority to AU2007246046A priority Critical patent/AU2007246046B2/en
Publication of WO2007124668A1 publication Critical patent/WO2007124668A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une composition pharmaceutique comportant un concentré élevé de polydatine. La composition contient de la polydatine, la méglumine et/ou la cyclodextrine. Ladite composition se présente sous une forme de solution aqueuse ou lyophilisée qui doit être préparée avant l'utilisation.
PCT/CN2007/001233 2006-04-28 2007-04-16 Composition pharmaceutique comportant un concentré élevé de polydatine WO2007124668A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2007246046A AU2007246046B2 (en) 2006-04-28 2007-04-16 Pharmaceutical composition comprising high concentrate of polydatin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200610076175.6 2006-04-28
CN2006100761756A CN101062044B (zh) 2006-04-28 2006-04-28 一种含高浓度虎杖苷的药物组合物

Publications (1)

Publication Number Publication Date
WO2007124668A1 true WO2007124668A1 (fr) 2007-11-08

Family

ID=38655061

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2007/001233 WO2007124668A1 (fr) 2006-04-28 2007-04-16 Composition pharmaceutique comportant un concentré élevé de polydatine

Country Status (3)

Country Link
CN (1) CN101062044B (fr)
AU (1) AU2007246046B2 (fr)
WO (1) WO2007124668A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2832348A4 (fr) * 2012-03-31 2015-09-02 Kunming Pharmaceutical Corp Procédé de dissolution d'un composé flavonoïde, d'un composé de glycoside carboné ou d'un composé de stilbène, et procédé de préparation d'une injection ou d'une poudre pour injection
US10624830B2 (en) 2017-11-30 2020-04-21 L'oreal Aqueous compositions with mangiferin for cosmetic applications
US10898420B2 (en) 2016-10-31 2021-01-26 L'oreal Compositions containing phenolic compounds having synergistic antioxidant benefits

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101791292A (zh) * 2010-04-13 2010-08-04 江庆澜 虎杖苷喷雾剂在作为哮喘治疗药物中的应用
CN107638571B (zh) * 2016-07-15 2021-07-06 中国人民解放军军事医学科学院毒物药物研究所 一种特考韦瑞口服药物组合物及其制备方法
CN107625967B (zh) * 2016-07-15 2021-07-06 中国人民解放军军事医学科学院毒物药物研究所 一种特考韦瑞注射用药物组合物及其制备方法
CN108670950B (zh) * 2018-06-29 2020-10-02 深圳海王医药科技研究院有限公司 一种不含有机溶剂的虎杖苷药物组合物及其制备方法
CN113143861B (zh) * 2021-06-15 2022-09-13 华北制药股份有限公司 一种注射用葛根素组合物及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1557297A (zh) * 2004-01-14 2004-12-29 江苏康缘药业股份有限公司 一种银杏内酯粉针剂及其制备方法
CN1709269A (zh) * 2005-07-08 2005-12-21 深圳海王药业有限公司 一种含虎杖苷的药物组合物及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1205938C (zh) * 2002-10-08 2005-06-15 深圳海王药业有限公司 具有改善哺乳动物微循环作用的产品
CN1220486C (zh) * 2002-11-15 2005-09-28 董英杰 白藜芦醇类化合物的β－环糊精或其衍生物的包合物及其制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1557297A (zh) * 2004-01-14 2004-12-29 江苏康缘药业股份有限公司 一种银杏内酯粉针剂及其制备方法
CN1709269A (zh) * 2005-07-08 2005-12-21 深圳海王药业有限公司 一种含虎杖苷的药物组合物及其应用

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2832348A4 (fr) * 2012-03-31 2015-09-02 Kunming Pharmaceutical Corp Procédé de dissolution d'un composé flavonoïde, d'un composé de glycoside carboné ou d'un composé de stilbène, et procédé de préparation d'une injection ou d'une poudre pour injection
US10898420B2 (en) 2016-10-31 2021-01-26 L'oreal Compositions containing phenolic compounds having synergistic antioxidant benefits
US10624830B2 (en) 2017-11-30 2020-04-21 L'oreal Aqueous compositions with mangiferin for cosmetic applications

Also Published As

Publication number Publication date
AU2007246046B2 (en) 2010-04-22
AU2007246046A1 (en) 2007-11-08
CN101062044B (zh) 2010-12-08
CN101062044A (zh) 2007-10-31

Similar Documents

Publication Publication Date Title
WO2007124668A1 (fr) Composition pharmaceutique comportant un concentré élevé de polydatine
CN111093674B (zh) 一种磺酰脲类药物的药物组合物及其制备方法
JP3656550B2 (ja) シクロデキストリンとタキソイドを含有する薬剤組成物
CN109983025B (zh) 包含5-胆甾烯-3,25-二醇,3-硫酸酯或其盐和至少一种环状寡糖的组合物
JP2009523771A (ja) 凍結乾燥した個体状タキサン類組成物、前記組成物を生成する方法、前記組成物の医薬調剤、前記組成物の調剤用キット。
JPH0611700B2 (ja) アントラサイクリングリコシド含有薬学的組成物
WO2018040989A1 (fr) Composition pharmaceutique sublinguale d'édaravone et de (+)-2-bornéol
ES2782106T3 (es) Formulaciones mejoradas de levosimendán para administración intravenosa como infusión o inyección y como concentrado de infusión
JP5413998B2 (ja) シクロデキストリンまたはその誘導体によるピノセンブリンの封入複合体
JP5535929B2 (ja) タキサン誘導体を含有する、改良された再構成時間を有する凍結乾燥医薬組成物及びその製法
JP2010510311A (ja) ベンゾジアゼピン構造のｒｓｖ阻害剤を含む安定な非経腸製剤
WO2005004874A1 (fr) Preparation medicinale lyophilisee stable contenant de la tetrodotoxine
WO2008086698A1 (fr) Forme injectable de forsythoside et préparation de celle-ci
KR101468153B1 (ko) 5α-안드로스테인-3β,5,6β-트리올 주사제 및 제조방법
US11318115B2 (en) Oral pharmaceutical composition of Tecovirimat and preparation method thereof
WO2010031346A1 (fr) Préparation de tétrodotoxine lyophilisée en poudre et son procédé de préparation
CN107019675B (zh) 注射用环磷腺苷冻干粉针剂药物组合物及质控方法和制法
JP2020535143A (ja) シポニモドを含む非経口製剤
JP2024515255A (ja) インスリン製剤及び早産児におけるインスリン製剤の使用方法
WO2017107894A1 (fr) Composé d'inclusion de médicament, composition à base de celui-ci et leur procédé de préparation
CN111789818A (zh) 注射用盐酸罂粟碱药物组合物及制备方法
WO2017107895A1 (fr) Composition orale et son procédé de préparation
CN112999175B (zh) 一种丁苯酞口服冻干粉及其制备方法和用途
WO2017198224A1 (fr) Composition pharmaceutique de rémimazolam
WO2023208009A1 (fr) Composition de nanoparticules instantanées et son procédé de préparation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07720806

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007246046

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2007246046

Country of ref document: AU

Date of ref document: 20070416

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 07720806

Country of ref document: EP

Kind code of ref document: A1